PASADENA, CA, April 12, 2022 — LIXTE Biotechnology Holdings, Inc. (NASDAQ: LIXT), a clinical-stage pharmaceutical company focused on developing and commercializing cancer therapies, announces that Professor René Bernards, Netherlands Cancer Institute (NKI), Amsterdam, presented new data … Continue reading LIXTE Biotechnology (NASDAQ: LIXT) Announces Preclinical Results of its Collaboration with the Netherlands Cancer Institute, Revealing Striking Anti-Cancer Activity of LB-100 In Novel Drug Combinations